View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2015	May 07, 2015
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Entity Registrant Name	SolarEdge Technologies Inc
Entity Central Index Key	0001419612
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		39,137,979

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2015

Jun. 30, 2014

CURRENT ASSETS:

Cash and cash equivalents

$ 135,204

$ 9,754

Restricted cash

3,575

1,602

Trade receivables, net

45,093

19,267

Prepaid expenses and other accounts receivable

25,312

13,151

Inventories

64,522

25,499

Total current assets

273,706

69,273

PROPERTY AND EQUIPMENT, NET

11,903

5,351

LONG-TERM LEASE DEPOSIT AND PREPAID EXPENSES

380

367

LONG-TERM DEFERRED CHARGES

Total assets

285,989

74,998

CURRENT LIABILITIES:

Short term bank loan

13,326

Current maturities of term loan

3,474

Trade payables

36,233

36,815

Employees and payroll accruals

6,017

5,210

Warranty obligations

7,661

5,496

Deferred revenues

1,098

1,729

Accrued expenses and other accounts payable

52,428

6,893

Total current liabilities

103,437

72,943

LONG-TERM LIABILITIES

Warranty obligations

20,238

12,685

Deferred revenues

6,995

4,252

Warrants to purchase common stock

2,830

765

Term loan

3,444

Lease incentive obligation

1,959

Total long-term liabilities

32,022

21,146

COMMITMENTS AND CONTINGENT LIABILITIES

Convertible preferred stock

116,203

Share capital

Common stock of $0.0001 par value - Authorized: 125,000,000 and 34,939,461 shares as of March 31, 2015 (unaudited) and June 30, 2014, respectively; issued and outstanding: 39,128,071 and 2,809,950 shares as of March 31, 2015 (unaudited) and June 30, 2014, respectively.

^[1]

Additional paid-in capital

280,040

5,878

Accumulated other comprehensive loss

(263)

(61)

Accumulated deficit

(129,251)

(141,111)

Total stockholders' equity (deficiency)

150,530

(135,294)

Total liabilities and stockholders' equity (deficiency)

$ 285,989

$ 74,998

[1]	Represents an amount less than $1

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2015	Jun. 30, 2014
Convertible Preferred Series A, B, C, D, D-1, D-2 and D-3 stock, par value	$ 0.0001	$ 0.0001
Convertible Preferred Series A, B, C, D, D-1, D-2 and D-3 stock, authorized shares	95,000,000	80,772,775
Convertible Preferred Series A, B, C, D, D-1, D-2 and D-3 stock, issued shares	0	75,422,773
Convertible Preferred Series A, B, C, D, D-1, D-2 and D-3 stock, outstanding shares	0	75,422,773
Convertible Preferred Series A, B, C, D, D-1, D-2 and D-3 stock, liquidation preferences	$ 0	$ 134,656
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	125,000,000	34,939,461
Common stock, issued shares	39,128,071	2,809,950
Common stock, outstanding shares	39,128,071	2,809,950

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) [Abstract]
Revenues	$ 86,399	$ 30,560	$ 226,658	$ 88,644
Cost of revenues	62,698	24,331	173,146	75,397
Gross profit	23,701	6,229	53,512	13,247
Operating expenses:
Research and development, net	5,490	4,864	15,317	13,686
Sales and marketing	6,422	4,592	17,541	12,372
General and administrative	1,990	1,318	4,270	3,120
Total operating expenses	13,902	10,774	37,128	29,178
Operating income (loss)	9,799	(4,545)	16,384	(15,931)
Financial expenses, net	3,436	626	3,378	2,317
Income (loss) before taxes on income	6,363	(5,171)	13,006	(18,248)
Taxes on income	398	67	1,146	88
Net income (loss)	$ 5,965	$ (5,238)	$ 11,860	$ (18,336)
Net basic earnings (loss) per share of common stock	$ 0.01	$ (1.87)	$ 0.02	$ (6.56)
Net diluted earnings (loss) per share of common stock	$ 0.01	$ (1.87)	$ 0.01	$ (6.56)
Weighted average number of shares used in computing net basic earnings (loss) per share of common stock	2,822,893	2,806,044	2,817,090	2,795,397
Weighted average number of shares used in computing net diluted earnings (loss) per share of common stock	7,099,046	2,806,044	5,534,903	2,795,397
Other comprehensive income (loss)
Change in comprehensive income (loss) related to foreign currency translation adjustments	$ (102)	$ (38)	$ (202)	$ (6)
Total comprehensive income (loss)	$ 5,863	$ (5,276)	$ 11,658	$ (18,342)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows used in operating activities:
Net income (loss)	$ 11,860	$ (18,336)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	1,647	1,451
Stock-based compensation related to employee and non-employee consultants stock options	1,750	791
Interest expenses related to Bank Loan		36
Financial expenses (income), net related to term loan	(992)	506
Remeasurement of warrants to purchase preferred and common stock	2,065	(45)
Changes in assets and liabilities:
Inventories	(39,071)	(10,406)
Prepaid expenses and other accounts receivable	(12,198)	(3,910)
Trade receivables, net	(25,993)	(4,102)
Trade payables	(1,264)	14,270
Employees and payroll accruals	883	1,059
Warranty obligations	9,718	6,743
Deferred revenues	2,116	(715)
Accrued expenses and other accounts payable	43,601	(229)
Lease incentive obligation	2,243
Net cash used in operating activities	(3,635)	(12,887)
Cash flows used in investing activities:
Purchase of property and equipment	(8,254)	(2,263)
Increase in restricted cash	(1,973)	(18)
Decrease (increase) in long-term deposits	(24)	26
Net cash used in investing activities	(10,251)	(2,255)
Cash flows from financing activities:
Proceeds from short-term bank loans	23,000	16,361
Repayments of short-term bank loans	(36,326)	(9,019)
Payments of term loan	(5,919)	(1,616)
Proceeds from initial public offering, net	133,944
Receipt on account of shares		7,115
Proceeds from exercise of employee stock options	46	51
Net cash provided by financing activities	139,457	13,561
Increase (decrease) in cash and cash equivalents	125,571	(1,581)
Cash and cash equivalents at the beginning of the period	9,754	13,142
Erosion due to exchange rate differences	(121)	(89)
Cash and cash equivalents at the end of the period	135,204	11,472
Supplemental disclosure of non-cash financing activities:
Issuance expenses not paid in cash	2,489
Series D-2 Preferred stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Convertible Preferred stock, net		669
Series E Convertible Preferred stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Convertible Preferred stock, net	$ 24,712

GENERAL

9 Months Ended

Mar. 31, 2015

GENERAL [Abstract]

GENERAL

NOTE 1:-

GENERAL

SolarEdge Technologies Inc. (the “Company”) and its subsidiaries design, develop, and sell an intelligent inverter solution that maximizes power generation at the individual photovoltaic (“PV”) module level while lowering the cost of energy produced by the solar PV system and providing comprehensive and advanced safety features. The Company's products consist mainly of (i) power optimizers which maximize energy throughput from each and every module through constant tracking of Maximum Power Point individually per module, (ii) inverters which invert direct current (DC) from the PV module to alternating current (AC) and (iii) a related cloud based monitoring platform, that collects and processes information from the power optimizers and inverters of a solar PV system to enable customers and system owners, as applicable, to monitor and manage the solar PV systems. The Company operates its business itself and through its wholly-owned subsidiaries: SolarEdge Technologies Ltd. in Israel; SolarEdge Technologies GmbH in Germany; SolarEdge Technologies (China) Co., Ltd in China; SolarEdge Technologies (Australia) PTY Ltd. in Australia; SolarEdge Technologies (Canada) Ltd. in Canada; SolarEdge Technologies (Holland) B.V. in the Netherlands; SolarEdge Technologies (UK) Ltd in United Kingdom; SolarEdge Technologies (Japan) Co., Ltd. in Japan and SolarEdge Technologies (France) in France (collectively, the “subsidiaries”). Except for SolarEdge Technologies Ltd in Israel, which carries out the research and development, management of manufacturing, global sales and support and management activities, the other subsidiaries are engaged solely in selling, marketing and support activities. The Company was incorporated in Delaware in August 2006 and began commercial sale of its products in January 2010.

Initial Public Offering:

On March 31, 2015, the Company closed its initial public offering (“IPO”) whereby 8,050,000 shares of common stock were sold by the Company to the public (inclusive of 1,050,000 shares of common stock pursuant to the full exercise of an overallotment option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were approximately $131,455, net of underwriting discounts and commissions and offering expenses payable by the Company. Upon the closing of the IPO, all shares of the Company's outstanding convertible preferred stock automatically converted into 28,247,923 shares of common stock, and outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock.

The significant accounting policies applied in the Company's audited annual consolidated financial statements as of June 30, 2014 are applied consistently in these financial statements.

Basis of Presentation:

The accompanying unaudited consolidated interim financial statements have been prepared in accordance with Article 10 of Regulation S-X, “Interim Financial Statements” and the rules and regulations for Form 10-Q of the Securities and Exchange Commission (the “SEC”). Pursuant to those rules and regulations, the Company has condensed or omitted certain information and footnote disclosure it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).

In management's opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly present its consolidated financial position, results of operations and cash flows. The Company's interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the 2014 consolidated financial statements and notes thereto included in the prospectus filed with the SEC on March 26, 2015 (the “Prospectus”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended June 30, 2014 included in the Prospectus.

The Company depends on two contract manufacturers and several limited or single source component suppliers. Reliance on these vendors makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs.

Two vendors collectively account for 39% (unaudited) and 59% of the Company's total trade payables as of March 31, 2015 (unaudited) and June 30, 2014 respectively.

Derivative financial instruments:

The Company accounts for derivatives and hedging based on ASC 815 (“Derivatives and Hedging”). ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.

The Company entered into derivative instrument arrangements to hedge the Company's exposure to currencies other than the U.S. dollar. These derivative instruments are not designated as cash flows hedges, as defined by ASC 815, and therefore all gains and losses were recorded immediately in the statement of operations, as financial expenses, net.

As of March 31, 2015, the Company recorded the fair value of derivative instruments in the amount of $314 in accrued expenses and other accounts payable.

As of June 30, 2014, the Company recorded the fair value of derivative instruments in the amount of $213 in prepaid expenses and other accounts receivable.

INVENTORIES

9 Months Ended

Mar. 31, 2015

INVENTORIES [Abstract]

INVENTORIES

NOTE 2:-

INVENTORIES

	March 31, 2015		June 30, 2014
	Unaudited

Raw materials	$	16,413	$	7,750
Finished goods		48,109		17,749

	$	64,522	$	25,499

WARRANTY OBLIGATIONS

9 Months Ended

Mar. 31, 2015

WARRANTY OBLIGATIONS [Abstract]

WARRANTY OBLIGATIONS

NOTE 3:-

WARRANTY OBLIGATIONS

Changes in the Company's product warranty liability for the three and nine months ended March 31, 2015 and 2014 were as follows:

	Three months ended March 31, 2015			Three months ended March 31, 2014			Nine months ended March 31, 2015			Nine months ended March 31, 2014

Balance, at beginning of period	$	24,296		$	15,613		$	18,181		$	10,378
Additions and adjustments to cost of revenues		4,988			2,274			13,456			9,539
Usage and current warranty expenses		(1,385	)		(766	)		(3,738	)		(2,796	)

Balance, at end of period		27,899			17,121			27,899			17,121
Less current portion		7,661			5,284			7,661			5,284

Long term portion	$	20,238		$	11,837		$	20,238		$	11,837

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK

9 Months Ended

Mar. 31, 2015

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK [Abstract]

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK

NOTE 4:-

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK

On December 28, 2012 (the “Agreement Date”), the Company entered into a loan facility agreement (the “Loan Agreement”) with a lender (the “Lender”), pursuant to which the Lender agreed to loan the Company up to $10,000. On the Agreement Date, the Company received a total of $10,000, less a $100 loan transaction fee paid to the Lender (the “Loan”). The Loan is for a period of 42 months and bears annual interest of 11.90%, which is to be paid monthly. The principal of the loan is to be paid in 33 monthly payments, beginning in September 2013, except for the last loan payment which was paid in advance on the Agreement Date. Repayment of the Loan and payment of all other amounts owed to the Lender is paid in Euro.

On January 26, 2015, the Company fully settled the amount borrowed from Lender under this Loan.

In connection with the Loan Agreement, the Company granted the Lender 563,014 warrants to purchase Series D-1 convertible preferred stock at an exercise price of $2.309 (the “Warrants”). Upon the closing of the IPO, the outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock. The Warrants are exercisable in whole or in part prior to earliest of (i) 12 months after a qualified initial public offering or (ii) immediately prior to the consumption of a merger or sale of all or substantially all of the Company's assets (“M&A Transaction”, and together with a qualified initial public offering, an “Exit Event”).

If (i) the Lender exercises all Warrants in full upon or after an Exit Event, and (ii) the intrinsic value of the Warrants upon such exercise is lower than $750, the Company shall pay to the Lender, in addition to any other amounts due to the Lender under the Loan Agreement, an amount equal to the difference between $750 and the Warrants' intrinsic value.

On the Agreement Date, the Company recorded its freestanding Warrants to purchase its convertible preferred stock in the amount of $778 as a liability at their fair value upon issuance, by utilizing an option pricing method. The fair value of the Warrants is subject to remeasurement at each balance sheet date with any change in value being reflected as financial expenses, net. As of March 31, 2015 (unaudited) and June 30, 2014, the Warrants liability has been measured at fair value in the amount of $2,830 (unaudited) and $765, respectively.

Upon exercise or expiration, the Warrants will be reclassified to stockholders' equity (deficiency), at which time the Warrant liability will no longer be subject to fair value accounting.

The following assumptions were used to estimate the value of the warrants to purchase convertible preferred stock and common stock:

	March 31, 2015			June 30, 2014
	Unaudited

Expected volatility		58	%		45	%
Risk-free rate		0.26	%		0.09	%
Dividend yield		0	%		0	%
Expected term (in years)		1.00			1.21

The warrants to purchase common stock are subject to re-measurement to fair value at each balance sheet date and any change in fair value is recognized as a component of financial expenses, net, on the statements of operations. The Company will continue to adjust the liability for changes in fair value until the exercise or expiration of the warrants.

The fair value of warrants to purchase common stock as of March 31, 2015 was determined using the Black-Scholes-Merton option-pricing model.

The expected terms of the warrants were based on the remaining contractual expiration period. The expected share price volatility for the shares was determined by examining the historical volatilities of a group of the Company's industry peers as there is no sufficient trading history of the Company's shares. The risk-free interest rate was calculated using the average of the published interest rates for U.S. Treasury zero-coupon issues with maturities that approximate the expected term. The dividend yield assumption was zero as there is no history of dividend payments.

REVOLVING CREDIT LINE

9 Months Ended

Mar. 31, 2015

REVOLVING CREDIT LINE [Abstract]

REVOLVING CREDIT LINE

NOTE 5:-

REVOLVING CREDIT LINE

In June 2011, the Company entered into an agreement for a revolving line of credit from a Bank Lender (the "Bank Lender"), which, as amended to date, permits aggregate borrowings of up to $20 million in an amount not to exceed 80% of the eligible trade receivables plus 65% of inventories in transit to customers and bears interest, payable monthly, at the Bank Lender's prime rate plus a margin of 0.75% to 2.75%. The average interest rate on the Company's outstanding borrowings as of June 30, 2014 was 4.9%.

As of June 30, 2014 and March 31, 2015 (unaudited), the Company met all its Bank Lender covenants.

On February 17, 2015, the Company amended and restated the agreement with the Bank Lender for a revolving line of credit, which permits aggregate borrowings of up to $40 million in an amount not to exceed 80% of the eligible accounts receivable and bears interest, payable monthly, at the Bank Lender's prime rate plus a margin of 0.5% to 2.0%. The amended and restated revolving line of credit will terminate, and outstanding borrowings will be payable, on December 31, 2016.

In connection with the amended and restated revolving line of credit, the Company granted the Bank Lender security interests in substantially all of the Company's assets, including a first-priority security interest in the Company's trade receivables, cash and cash equivalents. Financial covenants contained in the agreement require the Company to maintain EBITDA and liquidity at specified levels.

Specifically, the Company is required to maintain negative Adjusted EBITDA (defined in accordance with U.S. GAAP as (a) net income, plus (b) the extent deducted in the calculation of net income, interest, taxes, depreciation and amortization, plus (c) to the extent deducted in the calculation of net income, non-cash stock-based compensation) of no greater than ($1,500) as of March 31, 2015, and positive Adjusted EBITDA of at least (i) $1,500 as of June 30, 2015, (ii) $3,500 as of September 30, 2015 and December 31, 2015, (iii) $1,500 as of March 31, 2016 and (iv) $3,500 for the fiscal year ended June 30, 2016 and for each calendar quarter thereafter.

The Company is required to maintain liquidity (defined as unrestricted and unencumbered cash, plus availability under the amended and restated revolving line of credit) of $6,750.

The amended and restated revolving line of credit also contains covenants that restrict the Company's ability to dispose of assets, engage in business combinations (or permit a subsidiary to engage in business combinations), grant liens, borrow money, or pay dividends.

FAIR VALUE MEASUREMENTS

9 Months Ended

Mar. 31, 2015

FAIR VALUE MEASUREMENTS [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 6:-

FAIR VALUE MEASUREMENTS

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level to classify them for each reporting period. There have been no transfers between fair value measurements levels during the nine months ended March 31, 2015.

The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value:

Level 1-

Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2-

Include other inputs that are directly or indirectly observable in the marketplace.

Level 3-

Unobservable inputs which are supported by little or no market activity.

The following table sets forth the Company's assets and liabilities that were measured at fair value as of March 31, 2015 (unaudited) by level within the fair value hierarchy:

	Balance as of		Fair value measurements
	March 31,
Description	2015 (unaudited)		Level 1		Level 2		Level 3

Derivative instruments liability	$	314		-	$	314		-
Warrants to purchase Common Stock liability	$	2,830		-		-	$	2,830

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

LEASE INCENTIVE OBLIGATION

9 Months Ended

Mar. 31, 2015

LEASE INCENTIVE OBLIGATION[Abstract]

LEASE INCENTIVE OBLIGATION

NOTE 7:-

LEASE INCENTIVE OBLIGATION

The Company has a new operating lease agreement for a building in Hertzilia, Israel. In connection with this lease, the Company and its third party lessor (the "Lessor"), agreed that the Lessor would pay approximately $2,897 for certain leasehold improvements on behalf of the Company.

As of March 31, 2015 the Company received in cash $2,313 from the Lessor. These leasehold improvements are accounted for as a lease incentive obligation, which is recorded under long-term liabilities, net of the current portion recorded in accrued expenses and other accounts payable under current liabilities. The lease incentive obligation is being amortized over the life of the lease and as a reduction to rent expense.

COMMITMENTS AND CONTINGENT LIABILITIES

9 Months Ended

Mar. 31, 2015

COMMITMENTS AND CONTINGENT LIABILITIES [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 8:-

COMMITMENTS AND CONTINGENT LIABILITIES

Lease commitments:

The Company and its subsidiaries lease their operating facilities under non-cancelable operating lease agreements, which expire over the next ten years, with the last ending in December 2024.

The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises that are in effect as of March 31, 2015 (unaudited), are as follows:

Year ended June 30,	(Unaudited)

2015		525
2016		2,041
2017		2,027
2018		2,020
2019 and thereafter		10,150

		16,763

Rent expenses for the three months ended March 31, 2015 and 2014 were approximately $626 and $316, respectively.

Rent expenses for the nine months ended March 31, 2015 and 2014 were approximately $1,222 and $890, respectively.

Guarantees:

As of March 31, 2015 (unaudited), contingent liabilities exist regarding guarantees in the amount of $769, $50 and $81 in respect of office rent lease agreements, customs transactions and credit card limits, respectively.

Royalty and Governmental commitments:

As of March 31, 2015 (unaudited), the aggregate contingent liability to the Binational Industrial Research and Development Foundation (BIRD-F) amounted to approximately $1,123 (unaudited) which would be payable by the Company if it ever did generate revenues from products developed with funds provided by the BIRD-F.

As of March 31, 2015 (unaudited), the aggregate contingent liability to the Office of the Chief Scientist (the OCS) amounted to $729 (unaudited).

Contractual purchase obligations:

The Company has contractual obligations to purchase goods and raw materials. These contractual purchase obligations relate to inventories held by contract manufacturers and purchase orders initiated by the contract manufacturers and suppliers, which cannot be canceled without penalty. The Company utilizes third parties to manufacture its products. In addition, it acquires raw materials or other goods and services, including product components, by issuing to suppliers authorizations to purchase based on its projected demand and manufacturing needs. As of March 31, 2015 (unaudited), the Company had non-cancelable purchase obligations totaling approximately $73,480 (unaudited) out of which the Company already recorded a provision for loss in the amount of $1,084 (unaudited).

Legal claims:

From time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. These accruals are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular matter.

STOCK CAPITAL

9 Months Ended

Mar. 31, 2015

STOCK CAPITAL [Abstract]

STOCK CAPITAL

NOTE 9:-

STOCK CAPITAL

On March 23, 2015, the Company's board of directors and the requisite holders of the Company's capital stock consented to a 1-for-3 reverse stock split of the Company's common stock. As a result of the reverse stock split, (i) every Three shares of authorized, issued and outstanding common stock was decreased to one share of authorized, issued and outstanding common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased on a 1-for-3 basis, (iii) all share prices and exercise prices were proportionately increased. All common stock numbers, common stock prices, and exercise prices have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 1-for-3 reverse stock split.

Convertible Preferred Stock:

In September 2014, the Company entered into a stock purchase agreement with new investors, pursuant to which the Company issued 9,321,021 shares of the Company's Series E Convertible Preferred stock for cash consideration of $25,000, which was received by the end of October 2014.

Prior to the consummation of the Company's IPO on March 31, 2015, the Company had the following convertible preferred stock outstanding, all of which was converted to common stock in connection with the IPO on March 31, 2015 (see Note 1) which resulted in classification of convertible preferred stock temporary equity in the amount of $140,915 into stockholders' equity:

			Number of Shares
			of Common Stock
	Shares		issued upon
	Outstanding		conversion

Series A Preferred stock		15,558,830		5,186,276
Series B Preferred stock		18,760,196		6,253,398
Series C Preferred stock		15,984,655		5,328,217
Series D Preferred stock		16,024,251		5,341,416
Series D-1 Preferred stock		2,165,441		721,813
Series D-2 Preferred stock		2,598,528		866,175
Series D-3 Preferred stock		4,330,872		1,443,623
Series E Preferred stock		9,321,019		3,107,005
		84,743,792		28,247,923

Common Stock:

Authorized

Issued and outstanding

Number of shares

March 31,

2015

June 30,

2014

March 31,

2015

June 30,

2014

Unaudited

Stock of $0.001 par value:

Common stock

125,000,000

34,939,461

39,128,071

2,809,950

Stock option plans:

The Company's 2007 Global Incentive Plan (the “2007 Plan”) was adopted by the board of directors on August 30, 2007. As of June 30, 2014 a total of 5,234,212 options reserved for issuance under the 2007 plan. On March 31, 2015, once the Company completed its IPO, the 2007 Plan has been terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms and 379,358 available options for future grant were transferred to the Company's 2015 Global Incentive Plan (the “2015 Plan”) and are reserved for future issuances under the 2015 plan.

The 2015 Plan became effective upon the consummation of the IPO. As of March 31, 2015 (unaudited), a total of 1,822,484 (unaudited) options reserved for issuance under the 2015 Plan. The Share Reserve will automatically increase on January 1 of each year during the term of the 2015 Plan commencing on January 1 of the year following the year in which the 2015 Plan becomes effective in an amount equal to 5% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; provided, however, that the board of directors may provide that there will not be a January 1 increase in the Share Reserve in a given year or that the increase will be less than 5% of the shares of capital stock outstanding on the preceding December 31. The aggregate maximum number of shares of common stock that may be issued on the exercise of incentive stock options is 10,000,000.

As of June 30, 2014, an aggregate of 69,483 options were available for future grant under the 2007 Plan.

As of March 31, 2015 (unaudited), an aggregate of 1,822,484 (unaudited) options are still available for future grant under the 2015 Plan.

In addition, the Company adopted an Employee Stock Purchase Plan effective upon the consummation of the IPO. As of March 31, 2015 (unaudited), a total of 487,643 (unaudited) shares reserved for issuance under this plan. The number of shares of common stock reserved for issuance under the Company's Employee Stock Purchase Plan will increase automatically on January 1 of each year, for ten years, by the lesser of 1% of the total number of shares of the company's common stock outstanding on December 31 of the preceding calendar year or 487,643 shares. However, the board of directors may reduce the amount of the increase in any particular year at their discretion, including a reduction to zero.

A summary of the activity in the share options granted to employees and members of the board of directors for the nine months ended March 31, 2015 (unaudited) and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2014		4,007,116		$	2.13		6.82	$	6,384
Granted		2,116,123			5.05
Exercised		(20,198	)		2.25
Forfeited or expired		(43,261	)		3.30
Outstanding as of March 31, 2015 (unaudited)		6,059,780		$	3.14		7.31	$	113,884

Vested and expected to vest as of March 31, 2015 (unaudited)		5,740,735		$	3.08		7.21	$	108,234

Exercisable as of March 31, 2015 (unaudited)		3,323,010		$	2.06		5.78	$	66,028

The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the Company's common stock as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. The total intrinsic value of options exercised during the nine months ended March 31, 2015 (unaudited) was $397 (unaudited).

The weighted average grant date fair values of options granted to employees and executive directors during the nine months ended March 31, 2015 (unaudited) was $7.11 (unaudited).

The options outstanding as of March 31, 2015 (unaudited) have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	March 31,		contractual		March 31,		contractual
price	2015		Life in years		2015		Life in years

$0.87		490,165		3.39		490,165		3.39
$1.50 - $1.68		772,987		4.30		772,987		4.30
$2.01 - $2.46		2,085,549		6.55		1,711,477		6.47
$3.03 - $3.96		676,603		8.79		205,257		8.67
$5.01 - $5.04		2,001,148		9.67		143,124		9.64
$9.36		33,328		9.84		-		-

		6,059,780		7.31		3,323,010		5.78

Options issued to non-employee consultants:

The Company has granted options to purchase common shares to non-employee consultants as of March 31, 2015 as follows:

	Options
	outstanding				Exercisable
	as of				as of
Issuance	March 31,		Exercise		March 31,		Exercisable
Date	2015		price		2015		Through

July 31, 2008		33,333		0.87		33,333	July 31, 2018
January 26, 2011		5,000		2.01		5,000	January 26, 2021
January 26, 2012		33,333		2.46		33,333	January 26, 2022
October 24, 2012		6,666		2.46		4,166	October 24, 2022
January 23, 2013		6,250		3.03		4,861	January 23, 2023
January 27, 2014		4,998		3.51		1,361	January 27, 2024
May 1, 2014		6,000		3.51		1,667	May 1, 2024
September 17, 2014		20,343		3.96		1,631	September 17, 2024
October 29, 2014		6,668		5.01		556	October 29, 2024

		122,591				85,908

The Company had accounted for its options granted to non-employee consultants under the fair value method of ASC 505-50.

In connection with the grant of stock options to non-employee consultants, the Company recorded stock compensation expenses in the three months ended March 31, 2015 and 2014 in the amounts $970 and $278, respectively, and stock compensation expenses in the nine months ended March 31, 2015 and 2014 in the amounts $1,750 and $791, respectively.

Stock-based compensation expense for employees and consultants:

The Company recognized stock-based compensation expenses related to stock options granted to employees and non-employees in the consolidated statement of operations for the three and nine months ended on March 31, 2015 and 2014, as follows:

	Three months ended March 31, 2015		Three months ended March 31, 2014		Nine months ended March 31, 2015		Nine months ended March 31, 2014

Cost of revenues	$	140	$	33	$	254	$	80
Research and development		183		102		449		288
Selling and marketing		292		74		545		215
General and administrative		355		69		502		208

Total stock-based compensation expense	$	970	$	278	$	1,750	$	791

As of March 31, 2015 and June 30, 2014, there was a total unrecognized compensation expense of $10,020 and $2,277 related to non-vested equity-based compensation arrangements granted under the Company's Plan, respectively. These expenses are expected to be recognized during the period from April 1, 2015 through October 31, 2019 and July 1, 2014 through June 30, 2019, respectively.

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE

9 Months Ended

Mar. 31, 2015

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE [Abstract]

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE

NOTE 10:-

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE

Basic net earnings (loss) per share is computed by dividing the net earnings (loss) by the weighted-average number of shares of common stock outstanding during the period.

The total weighted average number of shares related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock and common stock, excluded from the calculation of diluted net earnings (loss) per share due to their anti-dilutive effect was 28,351,707 and 25,119,949 for the three months ended March 31, 2015 and 2014, respectively, and 27,378,784 and 25,018,621 for the nine months ended March 31, 2015 and 2014, respectively.

Basic and diluted earnings (loss) per share is presented in conformity with the two-class method for participating securities for the periods prior to their conversion. Under this method the earnings per share for each class of shares are calculated assuming 100% of the Company's earnings are distributed as dividends to each class of shares based on their contractual rights. In addition, since all classes other than common shares do not participate in losses, for the three and nine months ended March 31, 2014 (unaudited) these shares are not included in the computation of basic and diluted earnings per share.

For the three and nine months ended March 31, 2014 basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following table presents the computation of basic and diluted net earnings (loss) per share for the periods presented (in thousands, except per share data):

	Three months ended March 31,						Nine months ended March 31,
	2015			2014			2015			2014

	Unaudited
Numerator:
Net income (loss)		5,965			(5,238	)		11,860			(18,336	)
Dividends accumulated for the period		(5,923	)		-			(11,817	)		-
Net income (loss) available to shareholders of common stock		42			(5,238	)		43			(18,336	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic		2,822,893			2,806,044			2,817,090			2,795,397

Numerator:
Net income (loss)		5,965			(5,238	)		11,860			(18,336	)
Dividends accumulated for the period		(5,872	)		-			(11,782	)		-
Net income (loss) available to shareholders of common stock		93			(5,238	)		78			(18,336	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, diluted		7,099,046			2,806,044			5,534,903			2,795,397

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

9 Months Ended

Mar. 31, 2015

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS [Abstract]

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

NOTE 11:-

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

As of March 31, 2015 (unaudited) and June 30, 2014, the Company had a major customer that accounted for approximately 26.9% (unaudited) and 19.1% of the Company's consolidated revenues for the period of nine months and the year then ended, respectively.

As of March 31, 2015 (unaudited), two customers accounted for 25% (unaudited) and 17% (unaudited) of net accounts receivable, respectively. As of June 30, 2014, one customer accounted for 31% of net accounts receivable.

INVENTORIES (Tables)

9 Months Ended

Mar. 31, 2015

INVENTORIES [Abstract]

Schedule of inventories

	March 31, 2015		June 30, 2014
	Unaudited

Raw materials	$	16,413	$	7,750
Finished goods		48,109		17,749

	$	64,522	$	25,499

WARRANTY OBLIGATIONS (Tables)

9 Months Ended

Mar. 31, 2015

WARRANTY OBLIGATIONS [Abstract]

Schedule of warranty obligations

	Three months ended March 31, 2015			Three months ended March 31, 2014			Nine months ended March 31, 2015			Nine months ended March 31, 2014

Balance, at beginning of period	$	24,296		$	15,613		$	18,181		$	10,378
Additions and adjustments to cost of revenues		4,988			2,274			13,456			9,539
Usage and current warranty expenses		(1,385	)		(766	)		(3,738	)		(2,796	)

Balance, at end of period		27,899			17,121			27,899			17,121
Less current portion		7,661			5,284			7,661			5,284

Long term portion	$	20,238		$	11,837		$	20,238		$	11,837

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK (Tables)

9 Months Ended

Mar. 31, 2015

Warrants [Member]

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK [Line Items]

Schedule of assumptions used to estimate fair value of the warrants

	March 31, 2015			June 30, 2014
	Unaudited

Expected volatility		58	%		45	%
Risk-free rate		0.26	%		0.09	%
Dividend yield		0	%		0	%
Expected term (in years)		1.00			1.21

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Mar. 31, 2015

FAIR VALUE MEASUREMENTS [Abstract]

Schedule of assets and liabilities that were measured at fair value by level within the fair value hierarchy

	Balance as of		Fair value measurements
	March 31,
Description	2015 (unaudited)		Level 1		Level 2		Level 3

Derivative instruments liability	$	314		-	$	314		-
Warrants to purchase Common Stock liability	$	2,830		-		-	$	2,830

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

9 Months Ended

Mar. 31, 2015

COMMITMENTS AND CONTINGENT LIABILITIES [Abstract]

Schedule of future minimum lease commitments

Year ended June 30,	(Unaudited)

2015		525
2016		2,041
2017		2,027
2018		2,020
2019 and thereafter		10,150

		16,763

STOCK CAPITAL (Tables)

9 Months Ended

Mar. 31, 2015

STOCK CAPITAL [Abstract]

Schedule of convertible preferred stock

			Number of Shares
			of Common Stock
	Shares		issued upon
	Outstanding		conversion

Series A Preferred stock		15,558,830		5,186,276
Series B Preferred stock		18,760,196		6,253,398
Series C Preferred stock		15,984,655		5,328,217
Series D Preferred stock		16,024,251		5,341,416
Series D-1 Preferred stock		2,165,441		721,813
Series D-2 Preferred stock		2,598,528		866,175
Series D-3 Preferred stock		4,330,872		1,443,623
Series E Preferred stock		9,321,019		3,107,005
		84,743,792		28,247,923

Schedule of composition of common stock capital

Authorized

Issued and outstanding

Number of shares

March 31,

2015

June 30,

2014

March 31,

2015

June 30,

2014

Unaudited

Stock of $0.001 par value:

Common stock

125,000,000

34,939,461

39,128,071

2,809,950

Option [Member]

STOCK CAPITAL

Schedule of recognized stock-based compensation expenses

	Three months ended March 31, 2015		Three months ended March 31, 2014		Nine months ended March 31, 2015		Nine months ended March 31, 2014

Cost of revenues	$	140	$	33	$	254	$	80
Research and development		183		102		449		288
Selling and marketing		292		74		545		215
General and administrative		355		69		502		208

Total stock-based compensation expense	$	970	$	278	$	1,750	$	791

Option [Member] | Employees and members of the board of directors [Member]

STOCK CAPITAL

Summary of the activity in the share options

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2014		4,007,116		$	2.13		6.82	$	6,384
Granted		2,116,123			5.05
Exercised		(20,198	)		2.25
Forfeited or expired		(43,261	)		3.30
Outstanding as of March 31, 2015 (unaudited)		6,059,780		$	3.14		7.31	$	113,884

Vested and expected to vest as of March 31, 2015 (unaudited)		5,740,735		$	3.08		7.21	$	108,234

Exercisable as of March 31, 2015 (unaudited)		3,323,010		$	2.06		5.78	$	66,028

Schedule of exercise price range of options

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	March 31,		contractual		March 31,		contractual
price	2015		Life in years		2015		Life in years

$0.87		490,165		3.39		490,165		3.39
$1.50 - $1.68		772,987		4.30		772,987		4.30
$2.01 - $2.46		2,085,549		6.55		1,711,477		6.47
$3.03 - $3.96		676,603		8.79		205,257		8.67
$5.01 - $5.04		2,001,148		9.67		143,124		9.64
$9.36		33,328		9.84		-		-

		6,059,780		7.31		3,323,010		5.78

Option [Member] | Non-employee consultants

STOCK CAPITAL

Summary of the activity in the share options

	Options
	outstanding				Exercisable
	as of				as of
Issuance	March 31,		Exercise		March 31,		Exercisable
Date	2015		price		2015		Through

July 31, 2008		33,333		0.87		33,333	July 31, 2018
January 26, 2011		5,000		2.01		5,000	January 26, 2021
January 26, 2012		33,333		2.46		33,333	January 26, 2022
October 24, 2012		6,666		2.46		4,166	October 24, 2022
January 23, 2013		6,250		3.03		4,861	January 23, 2023
January 27, 2014		4,998		3.51		1,361	January 27, 2024
May 1, 2014		6,000		3.51		1,667	May 1, 2024
September 17, 2014		20,343		3.96		1,631	September 17, 2024
October 29, 2014		6,668		5.01		556	October 29, 2024

		122,591				85,908

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE (Tables)

9 Months Ended

Mar. 31, 2015

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE [Abstract]

Schedule of computation of basic and diluted net earnings (loss) per share

	Three months ended March 31,						Nine months ended March 31,
	2015			2014			2015			2014

	Unaudited
Numerator:
Net income (loss)		5,965			(5,238	)		11,860			(18,336	)
Dividends accumulated for the period		(5,923	)		-			(11,817	)		-
Net income (loss) available to shareholders of common stock		42			(5,238	)		43			(18,336	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic		2,822,893			2,806,044			2,817,090			2,795,397

Numerator:
Net income (loss)		5,965			(5,238	)		11,860			(18,336	)
Dividends accumulated for the period		(5,872	)		-			(11,782	)		-
Net income (loss) available to shareholders of common stock		93			(5,238	)		78			(18,336	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, diluted		7,099,046			2,806,044			5,534,903			2,795,397

GENERAL (Details) $ in Thousands		9 Months Ended	12 Months Ended
GENERAL (Details) $ in Thousands	Mar. 31, 2015 USD ($) shares	Mar. 31, 2015 USD ($) item shares	Jun. 30, 2014 USD ($)
General [Line Items]
Number of shares of common stock sold to the public	8,050,000
Number of shares of common stock sold pursuant to the full exercise of an overallotment option granted to the underwriters	1,050,000
Aggregate net proceeds received from offerings \| $	$ 131,455
Convertible preferred stock converted into number of shares of common stock	28,247,923
Warrants to purchase number of shares of common stock	187,671	187,671
Number of contract manufacturers \| item		2
Number of vendors \| item		2
Derivative financial instruments
Fair value of derivative instruments \| $	$ 314	$ 314
Fair value of derivative assets current \| $			$ 213
Trade payables [Member]
General [Line Items]
Concentration risk (as a percent)		39.00%	59.00%

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Jun. 30, 2014
INVENTORIES [Abstract]
Raw materials	$ 16,413	$ 7,750
Finished goods	48,109	17,749
Inventories	$ 64,522	$ 25,499

WARRANTY OBLIGATIONS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
WARRANTY OBLIGATIONS (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Changes in the Company's product warranty liability
Balance, at beginning of year	$ 24,296	$ 15,613	$ 18,181	$ 10,378
Additions and adjustments to cost of revenues	4,988	2,274	13,456	9,539
Usage and current warranty expenses	(1,385)	(766)	(3,738)	(2,796)
Balance, at end of year	27,899	17,121	27,899	17,121
Less current portion	7,661	5,284	7,661	5,284	$ 5,496
Long term portion	$ 20,238	$ 11,837	$ 20,238	$ 11,837	$ 12,685

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK (Details) $ / shares in Units, $ in Thousands	Dec. 28, 2012 USD ($) item $ / shares shares	Mar. 31, 2015 USD ($) shares	Jun. 30, 2014 USD ($)
TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK [Line Items]
Warrants granted to lender \| shares		187,671
Term loan [Member]
TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK [Line Items]
Loan amount	$ 10,000
Proceeds from loans	10,000
Loan transaction fee paid	$ 100
Debt instrument maturity period	42 months
Interest rate (as a percent)	11.90%
Number of monthly payments in which principal of loan to be paid \| item	33
Period after a qualified initial public offering considered while deciding warrants exercisability	12 months
Warrant intrinsic value threshold	$ 750
Warrant liability at fair value	$ 778	$ 2,830	$ 765
Term loan [Member] \| Series D-1 convertible preferred stock [Member]
TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK [Line Items]
Warrants granted to lender \| shares	563,014
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2,309

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK (Schedule of assumptions used to estimate fair value of the warrants) (Details) - Warrants [Member]	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014
TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK AND COMMON STOCK [Line Items]
Expected volatility	58.00%	45.00%
Risk-free rate	0.26%	0.09%
Dividend yield	0.00%	0.00%
Expected term (in years)	1 year	1 year 2 months 16 days

REVOLVING CREDIT LINE (Details) - Revolving line of credit [Member] - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Feb. 28, 2015	Jun. 30, 2011	Mar. 31, 2015	Jun. 30, 2014
REVOLVING CREDIT LINE [Line Items]
Aggregate borrowings	$ 40,000	$ 20,000
Maximum specified percentage of eligible trade receivables considered for determining maximum borrowing capacity	80.00%	80.00%
Maximum specified percentage of inventories in transit considered for determining maximum borrowing capacity		65.00%
Description of variable rate basis	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">Bank Lender's prime rate</div>		<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">Bank Lender's prime rate</div>
Average interest rate (as a percent)				4.90%
Termination date	Dec. 31, 2016
Maximum non-cash stock-based compensation considered calculation of net income	$ (1,500)
Minimum positive Adjusted EBITDA as of June 30, 2015	1,500
Minimum positive Adjusted EBITDA as of September 30, 2015	3,500
Minimum positive Adjusted EBITDA as of December 31, 2015	3,500
Minimum positive Adjusted EBITDA as of March 31, 2016	1,500
Minimum positive Adjusted EBITDA as of June 30, 2016	3,500
Amount of liquidity need to maintain	$ 6,750
Minimum [Member]
REVOLVING CREDIT LINE [Line Items]
Applicable margin (as a percent)	0.50%		0.75%
Maximum [Member]
REVOLVING CREDIT LINE [Line Items]
Applicable margin (as a percent)	2.00%		2.75%

FAIR VALUE MEASUREMENTS (Details) - Recurring basis [Member] $ in Thousands	9 Months Ended
	Mar. 31, 2015 USD ($)
FAIR VALUE MEASUREMENTS [Line Items]
Transfer from Level 1 to Level 2	$ 0
Transfer from Level 2 to Level 1	0
Transfer into Level 3	0
Transfer out of Level 3	0
Estimated fair value [Member] \| Derivative instruments liability [Member]
FAIR VALUE MEASUREMENTS [Line Items]
Fair value liability	314
Estimated fair value [Member] \| Warrants to purchase Common Stock liability [Member]
FAIR VALUE MEASUREMENTS [Line Items]
Fair value liability	2,830
Level 2 [Member] \| Derivative instruments liability [Member]
FAIR VALUE MEASUREMENTS [Line Items]
Fair value liability	314
Level 3 [Member] \| Warrants to purchase Common Stock liability [Member]
FAIR VALUE MEASUREMENTS [Line Items]
Fair value liability	$ 2,830

LEASE INCENTIVE OBLIGATION (Details) $ in Thousands	Mar. 31, 2015 USD ($)
LEASE INCENTIVE OBLIGATION[Abstract]
Operating lease receivable	$ 2,897
Received in cash from the Lessor	$ 2,313

COMMITMENTS AND CONTINGENT LIABILITIES (Schedule of Future Minimum Lease Commitments) (Details) $ in Thousands	Mar. 31, 2015 USD ($)
Future minimum lease commitments
2015	$ 525
2016	2,041
2017	2,027
2018	2,020
2019 and thereafter	10,150
Future minimum lease commitments amount	$ 16,763

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Lease commitments, Guarantees, Royalty commitments, Governmental commitments, Contractual purchase obligations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Lease commitments
Contract term			10 years
Rent expenses	$ 626	$ 316	$ 1,222	$ 890
Royalty commitments
Aggregate contingent liability to the BIRD-F amount	1,123		1,123
Governmental commitments
Governmental commitments amount	729		729
Contractual purchase obligations
Non-cancelable purchase obligations	73,480		73,480
Provision for contractual inventory purchase obligations	1,084		1,084
Office rent lease agreements [Member]
Guarantees [line Items]
Guarantees amount	769		769
Customs transactions [Member]
Guarantees [line Items]
Guarantees amount	50		50
Credit card limits [Member]
Guarantees [line Items]
Guarantees amount	$ 81		$ 81

STOCK CAPITAL (Convertible Preferred Stock) (Details) - USD ($) $ in Thousands		1 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2014	Mar. 31, 2015
Convertible Preferred Stock [Line Items]
Stock issued for cash consideration (in shares)	8,050,000
Classification of convertible preferred stock temporary equity into stockholders' equity			$ 140,915
Shares Outstanding			84,743,792
Number of Shares of Common Stock issued upon conversion			28,247,923
Series A Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			15,558,830
Number of Shares of Common Stock issued upon conversion			5,186,276
Series B Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			18,760,196
Number of Shares of Common Stock issued upon conversion			6,253,398
Series C Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			15,984,655
Number of Shares of Common Stock issued upon conversion			5,328,217
Series D Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			16,024,251
Number of Shares of Common Stock issued upon conversion			5,341,416
Series D-1 Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			2,165,441
Number of Shares of Common Stock issued upon conversion			721,813
Series D-2 Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			2,598,528
Number of Shares of Common Stock issued upon conversion			866,175
Series D-3 Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Shares Outstanding			4,330,872
Number of Shares of Common Stock issued upon conversion			1,443,623
Series E Preferred stock [Member]
Convertible Preferred Stock [Line Items]
Stock issued for cash consideration (in shares)		9,321,021
Stock issued for cash consideration		$ 25,000
Shares Outstanding			9,321,019
Number of Shares of Common Stock issued upon conversion			3,107,005

STOCK CAPITAL (Common Stock) (Details)	9 Months Ended
STOCK CAPITAL (Common Stock) (Details)	Mar. 31, 2015 $ / shares shares	Jun. 30, 2014 $ / shares shares
STOCK CAPITAL [Abstract]
Reverse stock split ratio	0.33
Common stock capital
Par value \| $ / shares	$ 0.0001	$ 0.0001
Authorized	125,000,000	34,939,461
Issued and outstanding	39,128,071	2,809,950

STOCK CAPITAL (Stock option plans) (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
2015 Plan
Stock option plans
Number of options reserved for issuance under the plan		10,000,000
Option [Member]
Stock option plans
Number of options reserved for issuance under the plan			5,234,212
Number of options are available for future grant under the plan		379,358
Unrecognized compensation expense		$ 10,020	$ 2,277
Option [Member] \| 2007 Plan
Stock option plans
Number of options are available for future grant under the plan			69,483
Option [Member] \| 2015 Plan
Stock option plans
Number of options reserved for issuance under the plan		1,822,484
Percentage of common shares increase automatically in each year		5.00%
Option [Member] \| Maximum [Member] \| 2015 Plan
Stock option plans
Percentage of common shares increase automatically in each year	5.00%
Option [Member] \| Employees and members of the board of directors [Member]
Stock option plans
Intrinsic value of options exercised		$ 397
Weighted average grant date fair values options granted to employees and executive directors		$ 7.11
Employee Stock Purchase Plan [Member]
Stock option plans
Number of options reserved for issuance under the plan		487,643
Percentage of common shares increase automatically in each year		1.00%
Period of plan increase automatically number of shares		10 years

STOCK CAPITAL (Summary of the activity in the share options) (Details) - Option [Member] - Employees and members of the board of directors [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014
Number of options
Outstanding at the beginning of the period	4,007,116
Granted	2,116,123
Exercised	(20,198)
Forfeited or expired	(43,261)
Outstanding at the end of the period	6,059,780	4,007,116
Weighted average exercise price
Outstanding at the beginning of the period	$ 2.13
Granted	5.05
Exercised	2.25
Forfeited or expired	3.30
Outstanding at the end of the period	$ 3.14	$ 2.13
Weighted average remaining contractual term in years
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 3 months 22 days	6 years 9 months 25 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 3 months 22 days	6 years 9 months 25 days
Aggregate intrinsic Value
Outstanding at the beginning of the period	$ 6,384
Outstanding at the end of the period	$ 113,884	$ 6,384
Vested and expected to vest at the end of the period
Number of options	5,740,735
Weighted average exercise price	$ 3.08
Weighted average remaining contractual term in years	7 years 2 months 16 days
Aggregate intrinsic Value	$ 108,234
Exercisable at the end of the period
Number of options	3,323,010
Weighted average exercise price	$ 2.06
Weighted average remaining contractual term in years	5 years 9 months 11 days
Aggregate intrinsic Value	$ 66,028

STOCK CAPITAL (Schedule of exercise price ranges) (Details) - Employees and members of the board of directors [Member]	9 Months Ended
	Mar. 31, 2015 $ / shares shares
Range of exercise price [Line Items]
Options outstanding	6,059,780
Weighted average remaining contractual Life in years	7 years 3 months 22 days
Options exercisable	3,323,010
Weighted average remaining contractual Life in years	5 years 9 months 11 days
$0.87 [Member]
Range of exercise price [Line Items]
Exercise price \| $ / shares	$ 0.87
Options outstanding	490,165
Weighted average remaining contractual Life in years	3 years 4 months 20 days
Options exercisable	490,165
Weighted average remaining contractual Life in years	3 years 4 months 20 days
$1.50 - $1.68 [Member]
Range of exercise price [Line Items]
Range of exercise price, lower \| $ / shares	$ 1.50
Range of exercise price, upper \| $ / shares	$ 1.68
Options outstanding	772,987
Weighted average remaining contractual Life in years	4 years 3 months 18 days
Options exercisable	772,987
Weighted average remaining contractual Life in years	4 years 3 months 18 days
$2.01 - $2.46 [Member]
Range of exercise price [Line Items]
Range of exercise price, lower \| $ / shares	$ 2.01
Range of exercise price, upper \| $ / shares	$ 2.46
Options outstanding	2,085,549
Weighted average remaining contractual Life in years	6 years 6 months 18 days
Options exercisable	1,711,477
Weighted average remaining contractual Life in years	6 years 5 months 19 days
$3.03 - $3.96 [Member]
Range of exercise price [Line Items]
Range of exercise price, lower \| $ / shares	$ 3.03
Range of exercise price, upper \| $ / shares	$ 3.96
Options outstanding	676,603
Weighted average remaining contractual Life in years	8 years 9 months 14 days
Options exercisable	205,257
Weighted average remaining contractual Life in years	8 years 8 months 1 day
$5.01 - $5.04 [Member]
Range of exercise price [Line Items]
Range of exercise price, lower \| $ / shares	$ 5.01
Range of exercise price, upper \| $ / shares	$ 5.04
Options outstanding	2,001,148
Weighted average remaining contractual Life in years	9 years 8 months 1 day
Options exercisable	143,124
Weighted average remaining contractual Life in years	9 years 7 months 20 days
$9.36 [Member]
Range of exercise price [Line Items]
Exercise price \| $ / shares	$ 9.36
Options outstanding	33,328
Weighted average remaining contractual Life in years	9 years 10 months 2 days
Options exercisable
Weighted average remaining contractual Life in years

STOCK CAPITAL (Options issued to non-employee consultants) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Stock option plans
Stock compensation expenses	$ 970	$ 278	$ 1,750	$ 791
Option [Member] \| Non-employee consultants
Stock option plans
Options outstanding at the end of the period	122,591		122,591
Exercisable at the end of the period	85,908		85,908
Option [Member] \| Non-employee consultants \| July 31, 2008
Stock option plans
Options outstanding at the end of the period	33,333		33,333
Exercise price	$ 0.87		$ 0.87
Exercisable at the end of the period	33,333		33,333
Option [Member] \| Non-employee consultants \| January 26, 2011
Stock option plans
Options outstanding at the end of the period	5,000		5,000
Exercise price	$ 2.01		$ 2.01
Exercisable at the end of the period	5,000		5,000
Option [Member] \| Non-employee consultants \| January 26, 2012
Stock option plans
Options outstanding at the end of the period	33,333		33,333
Exercise price	$ 2.46		$ 2.46
Exercisable at the end of the period	33,333		33,333
Option [Member] \| Non-employee consultants \| October 24, 2012
Stock option plans
Options outstanding at the end of the period	6,666		6,666
Exercise price	$ 2.46		$ 2.46
Exercisable at the end of the period	4,166		4,166
Option [Member] \| Non-employee consultants \| January 23, 2013
Stock option plans
Options outstanding at the end of the period	6,250		6,250
Exercise price	$ 3.03		$ 3.03
Exercisable at the end of the period	4,861		4,861
Option [Member] \| Non-employee consultants \| January 27, 2014
Stock option plans
Options outstanding at the end of the period	4,998		4,998
Exercise price	$ 3.51		$ 3.51
Exercisable at the end of the period	1,361		1,361
Option [Member] \| Non-employee consultants \| May 1, 2014
Stock option plans
Options outstanding at the end of the period	6,000		6,000
Exercise price	$ 3.51		$ 3.51
Exercisable at the end of the period	1,667		1,667
Option [Member] \| Non-employee consultants \| September 17, 2014
Stock option plans
Options outstanding at the end of the period	20,343		20,343
Exercise price	$ 3.96		$ 3.96
Exercisable at the end of the period	1,631		1,631
Option [Member] \| Non-employee consultants \| October 29, 2014
Stock option plans
Options outstanding at the end of the period	6,668		6,668
Exercise price	$ 5.01		$ 5.01
Exercisable at the end of the period	556		556

STOCK CAPITAL (Schedule of stock-based compensation expense for employees and consultants) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Stock-based compensation expenses
Total stock-based compensation expense	$ 970	$ 278	$ 1,750	$ 791
Cost of revenues [Member]
Stock-based compensation expenses
Total stock-based compensation expense	140	33	254	80
Research and development [Member]
Stock-based compensation expenses
Total stock-based compensation expense	183	102	449	288
Selling and marketing [Member]
Stock-based compensation expenses
Total stock-based compensation expense	292	74	545	215
General and administrative [Member]
Stock-based compensation expenses
Total stock-based compensation expense	$ 355	$ 69	$ 502	$ 208

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE (Narrative) (Details) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE [Abstract]
Total weighted average number of shares related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock and common stock, excluded from the calculation of diluted net earnings (loss) per share due to their anti-dilutive effect	28,351,707	25,119,949	27,378,784	25,018,621

BASIC AND DILUTED NET EARNINGS (LOSS) PER SHARE (Schedule of Computation of Basic and Diluted Net Earnings (Loss) Per Share) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net income (loss)	$ 5,965	$ (5,238)	$ 11,860	$ (18,336)
Dividends accumulated for the period	(5,923)		(11,817)
Net income (loss) available to shareholders of common stock	$ 42	$ (5,238)	$ 43	$ (18,336)
Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic (in shares)	2,822,893	2,806,044	2,817,090	2,795,397
Numerator:
Net income (loss)	$ 5,965	$ (5,238)	$ 11,860	$ (18,336)
Dividends accumulated for the period	(5,872)		(11,782)
Net income (loss) available to shareholders of common stock	$ 93	$ (5,238)	$ 78	$ (18,336)
Denominator:
Shares used in computing net earnings (loss) per share of common stock, diluted (in shares)	7,099,046	2,806,044	5,534,903	2,795,397

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS (Details)	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014
Revenues [Member] \| Major customer [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)	26.90%	19.10%
Accounts receivable [Member] \| Customer one [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)	25.00%
Accounts receivable [Member] \| Customer two [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)	17.00%
Accounts receivable [Member] \| Customer three [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)		31.00%